Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. （開啟新視窗）

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

來源‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

檢索‎: PubMed 21602718

DOI碼‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 （開啟新視窗）

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? （開啟新視窗）

Banan M.

來源‎: Ann Hematol 2013;92(3):289-99.

檢索‎: PubMed 23318979

DOI碼‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 （開啟新視窗）

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. （開啟新視窗）

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

來源‎: Transfusion 2007;47(10):1830-6.

檢索‎: PubMed 17880608

DOI碼‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 （開啟新視窗）

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. （開啟新視窗）

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

來源‎: Blood 1996;87(3):887-92.

檢索‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 （開啟新視窗）

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. （開啟新視窗）

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

來源‎: Iran J Blood Cancer 2009;1(4):147-50.

檢索‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en （開啟新視窗）

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. （開啟新視窗）

Karimi M, Cohan N, Pishdad P.

來源‎: Hematology 2015;20(1):53-7.

檢索‎: PubMed 24717020

DOI碼‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 （開啟新視窗）

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. （開啟新視窗）

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

來源‎: Int J Hematol 2012;95(1):51-6.

檢索‎: PubMed 22180324

DOI碼‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 （開啟新視窗）

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. （開啟新視窗）

Kosaryan M, Karami H, Zafari M, Yaghobi N.

來源‎: Hemoglobin 2014;38(2):115-8.

檢索‎: PubMed 24471558

DOI碼‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 （開啟新視窗）

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. （開啟新視窗）

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

來源‎: Blood 2013;121(12):2199-212.

檢索‎: PubMed 23315167

DOI碼‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 （開啟新視窗）

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. （開啟新視窗）

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

來源‎: Sci Rep. 2022;12(1):2752.

檢索‎: PubMed 35177777

DOI碼‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ （開啟新視窗）

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. （開啟新視窗）

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

來源‎: Haematologica 2004;89(10):1172-8.

檢索‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 （開啟新視窗）

Hydroxyurea therapy in 49 patients with major beta-thalassemia. （開啟新視窗）

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

來源‎: Arch Iran Med 2009;12(3):295-7.

檢索‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 （開啟新視窗）

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. （開啟新視窗）

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

來源‎: Eur J Haematol 1996;56(5):326-8.

檢索‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 （開啟新視窗）

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. （開啟新視窗）

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

來源‎: J Matern Fetal Med 1999;8(1):1-7.

檢索‎: PubMed 10052837

DOI碼‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 （開啟新視窗）

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. （開啟新視窗）

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

來源‎: Acta Haematol 2004;111(4):189-95.

檢索‎: PubMed 15153710

DOI碼‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 （開啟新視窗）

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. （開啟新視窗）

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

來源‎: Ann Hematol 2001;80(8):492-5.

檢索‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 （開啟新視窗）

Fetal globin induction--can it cure beta thalassemia? （開啟新視窗）

Perrine SP.

來源‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

檢索‎: PubMed 16304357

DOI碼‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 （開啟新視窗）